Priority 18 from the Neurodevelopmental Disorders Canada PSP
| UNCERTAINTY: How do co-occurring disorders impact treatment decisions for individuals with a neurodevelopmental disorder? (JLA PSP Priority 18) | |
|---|---|
| Overall ranking | 18 |
| JLA question ID | 0056/18 |
| Explanatory note | Neurodevelopmental disorders often co-occur with other conditions or diagnoses, for example epilepsy, addiction, psychosis, anxiety, depression or another neurodevelopmental disorder. This question aims to understand what treatments and approaches are most effective when an individual who has multiple conditions, and what impact co-occurring disorders have on treatment effectiveness. This question also pushes researchers to explore whether current treatments should be adapted to consider co-occurring conditions or whether similar treatment approaches are applicable across multiple disorders. |
| Evidence | Systematic reviews: 1) Jackson CF, Makin SM, Marson AG, Kerr M. Pharmacological interventions for epilepsy in people with intellectual disabilities. Cochrane Database of Systematic Reviews 2015, Issue 9. Art. No.: CD005399. DOI: 10.1002/14651858.CD005399.pub3.; 2)Jackson CF, Makin SM, Marson AG, KerrM. Non-pharmacological interventions for people with epilepsy and intellectual disabilities. Cochrane Database of Systematic Reviews 2015, Issue 9. Art. No.: CD005502. DOI:10.1002/14651858.CD005502.pub3.; 3) Ayub M, Saeed K, Munshi TA, Naeem F. Clozapine for psychotic disorders in adults with intellectual disabilities. Cochrane Database of Systematic Reviews 2015, Issue 9. Art. No.: CD010625. DOI: 10.1002/14651858.CD010625.pub2. |
| Health Research Classification System category | Mental Health |
| Extra information provided by this PSP | |
|---|---|
| Original uncertainty examples | [What is the] effect of comorbid disorders (such as anxiety, depression) on treatments? ~ How co-morbid disorders impact the manifestation of the disorder and its treatment; investigate multiple diagnoses interactions and relationships |
| Submitted by | Mostly family members/carers, some clinicians |
| PSP information | |
|---|---|
| PSP unique ID | 0056 |
| PSP name | Neurodevelopmental Disorders (Canada) |
| Total number of uncertainties identified by this PSP. | 63 (To see a full list of all uncertainties identified, please see the detailed spreadsheet held on the JLA website) |
| Date of priority setting workshop | 28 September 2017 |